Stocks · News reference

B. Riley Securities Maintains Buy on Macrogenics, Raises Price Target to $11

Aug 17, 2026, 4:38 PMBenzinga Newsdesk

B. Riley Securities analyst Mayank Mamtani maintains Macrogenics (NASDAQ:MGNX) with a Buy and raises the price target from $9 to $11.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 13, 2026, 9:52 PMBenzinga Newsdesk
UPDATE: Macrogenics Q2 Adj. EPS $(0.27) Misses $(0.13) Estimate, Sales $32.832M Miss $67.456M Estimate
Macrogenics (NASDAQ:MGNX) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.13) by 107.69 percent. This is a 52.63 percent increase over losses of $(0.57) per share from
MGNX
BenzingaAug 13, 2026, 8:32 PMBenzinga Newsdesk
Macrogenics Q2 EPS $(0.31) Misses $0.02 Estimate, Sales $32.832M Miss $67.456M Estimate
MGNX
SEC EDGARAug 13, 2026, 8:07 PMSEC EDGAR
8-K filing — MACROGENICS INC (MGNX)
Filed: 2026-08-13 AccNo: 0001125345-26-000054 Size: 353 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
MGNX